All Stories

  1. Intranasal corticosteroids in allergic rhinitis in COVID‐19 infected patients: An ARIA‐EAACI statement
  2. Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement
  3. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK‐air ® App
  4. Aligning the Good Practice MASK With the Objectives of the European Innovation Partnership on Active and Healthy Ageing
  5. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence
  6. Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?
  7. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases
  8. ARIA-Versorgungspfade für die Allergenimmuntherapie 2019
  9. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases—Meeting Report (Part 2)
  10. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases—Meeting Report (Part 1)
  11. 2019 ARIA Care pathways for allergen immunotherapy
  12. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study
  13. ARIA pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy”
  14. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma
  15. Use of complementary medicine among patients with allergic rhinitis: an Italian nationwide survey
  16. The Characteristics of Severe Chronic Upper-Airway Disease (SCUAD) in Patients with Allergic Rhinitis: A Real-Life Multicenter Cross-Sectional Italian Study
  17. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence
  18. Urban air pollution and climate change: “The Decalogue: Allergy Safe Tree” for allergic and respiratory diseases care
  19. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology
  20. The Psoriasis Pathogenesis and the Metabolic Risk
  21. Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study
  22. Importance of hypersensitivity in adverse reactions to drugs in the elderly
  23. The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire Using Mobile Technology: The MASK Study
  24. A Multicenter Study of IgE Sensitization to Anisakis simplex and Diet Recommendations
  25. Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study
  26. Immunosenescence in aging: between immune cells depletion and cytokines up-regulation
  27. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report
  28. Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control
  29. How to fit allergen immunotherapy in the elderly
  30. The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study
  31. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project)
  32. Shrimp Allergy: Analysis of Commercially Available Extracts for In Vivo Diagnosis
  33. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement
  34. Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms
  35. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
  36. Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies
  37. Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA
  38. Building bridges for innovation in ageing: Synergies between Action Groups of the EIP on AHA
  39. Cytokine Profile in Patients Infected with Anisakis simplex in Endemic Areas: Dietary Intervention with Polyphenols: A Working Hypothesis
  40. Guidelines for the use and interpretation of diagnostic methods in adult food allergy
  41. Management of allergic disease in the elderly: key considerations, recommendations and emerging therapies
  42. Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly
  43. Management of Chronic Spontaneous Urticaria in the Elderly
  44. Anisakis Simplex Infestation and Immune-Mediated Responses
  45. A Survey of Clinical Features of Allergic Rhinitis in Adults
  46. <b><i>Anisakis</i></b> <b><i>simplex</i></b> Hypersensitivity Is Associated with Chronic Urticaria in Endemic Areas
  47. Diet and myocardial infarction: A nested case-control study in a cohort of elderly subjects in a Mediterranean area of southern Italy
  48. Clinical and cytologic characteristics of allergic rhinitis in elderly patients
  49. An approach to urticaria in the elderly patients
  50. Sensitization to Horse Allergens in Italy: A Multicentre Study in Urban Atopic Subjects without Occupational Exposure
  51. Anisakiasis, an Underestimated Infection: Effect on Intestinal Permeability of Anisakis simplex–Sensitized Patients
  52. Allergic and non-allergic rhinitis in swimmers: clinical and cytological aspects
  53. Adverse drug reactions as the cause of emergency department admission: focus on the elderly
  54. Incidence of allergic diseases in an elderly population
  55. PA6 IS THE EOSINOPHIL CATIONIC PROTEIN (ECP) IN CORD BLOOD A PREDICTIVE MARKER OF ALLERGIC RISK?
  56. Clinical Data and Inflammation Parameters in Patients with Cypress Allergy Treated with Sublingual Swallow Therapy and Subcutaneous Immunotherapy
  57. Sensitization, asthma and allergic disease in young soccer players
  58. Allergic contact dermatitis from timolol complicating choroidal melanoma-related glaucoma
  59. Editorial [Hot Topic: Advances in Diagnosing Drug Hypersensitivity Reactions (Executive Editors: A. Romano and M. Ventura)]
  60. Hypersensitivity Reactions to Last Generation Chimeric, Umanized and Human Recombinant Monoclonal Antibodies for Therapeutic Use
  61. Antiinflammatory Effects of H1-Antihistamines: Clinical and Immunological Relevance
  62. Local and Systemic Reactions Occurring During Immunotherapy: An Epidemiological Evaluation and a Prospective Safety-Monitoring Study
  63. Specific immunotherapy for house-dust mite in a patient with anisakis allergy
  64. Validity and reproducibility of morphologic analysis of nasal secretions obtained using ultrasonic nebulization of hypertonic solution
  65. Adverse reaction to specific immunotherapy for house‐dust mite in a patient with Anisakis allergy
  66. Anaphylaxis Induced by Intramuscular Betamethasone Disodium Phosphate: Reflections on a Clinical Case
  67. Is black henna responsible for asthma and cross reactivity with latex?
  68. Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs
  69. Non Allergic Rhinitis In Competitive Swimmers
  70. Intestinal permeability in patients with adverse reactions to food
  71. Latex Allergy and Sensitization in Cities: A Survey in a Population at Risk
  72. Editorial [Hot Topic: An Update on the Diagnosis of Allergic and Non-Allergic Drug Hypersensitivity (Executive Editors: M.T. Ventura and A. Romano) ]
  73. Hypersensitivity to Aromatic Anticonvulsants: In Vivo and In Vitro Cross-Reactivity Studies
  74. Cross-Reactivity in Cell-Mediated and IgE-Mediated Hypersensitivity to Glucocorticoids
  75. Hypersensitivity Reactions to Complementary and Alternative Medicine Products
  76. Hypersensitivity Reactions to Ophthalmic Products
  77. Rhinitis and asthma in athletes: an ARIA document in collaboration with GA2LEN
  78. Patients with Hereditary Hemorrhagic Telangectasia (HHT) Exhibit a Deficit of Polymorphonuclear Cell and Monocyte Oxidative Burst and Phagocytosis: A Possible Correlation with Altered Adaptive Immune Responsiveness in HHT
  79. Airway inflammation in subjects with gastro‐oesophageal reflux and gastro‐oesophageal reflux‐related asthma
  80. Cutaneous adverse drug reactions to Fluticasone propionate and Deflazacort in an asthmatic patient
  81. Anaphylaxis to hydrocortisone hemisuccinate with cross-sensitivity to related compounds in a paediatric patient
  82. Allergy, asthma and markers of infections among Albanian migrants to Southern Italy
  83. Allergic and Pseudoallergic Reactions Induced by Glucocorticoids: A Review
  84. Alternative glucocorticoids for use in cases of adverse reaction to systemic glucocorticoids: a study on 10 patients
  85. Eyedrop‐Induced Allergy: Clinical Evaluation and Diagnostic Protocol
  86. Contact dermatitis in students practicing sports: incidence of rubber sensitisation
  87. Retrospective study on fluticasone propionate aqueous nasal spray efficacy in patients with allergic rhinitis: evaluation of clinical and laboratory parameters
  88. Latex and amoxicillin‐induced asthma
  89. Allergic contact dermatitis due to epirubicin
  90. Latex and amoxicillin‐provoked occupational asthma
  91. Retrospective Study of Adverse Reactions to Non Steroid Anti-Inflammatory Drugs (Nsaids): Predictive Value of Controlled Challe with Alternative Drugs
  92. Modulation of Eosinophilic Chemotaxis with Azelastine and Budesonide in Allergic Patients
  93. Eosinophils in Allergic Diseases: Immuno-Pharmacological Regulation
  94. Allergic bronchial asthma: eosinophil chemotaxis and antihistaminic drug modulation
  95. Human melanoma metastasis culture supernatant contains chemotactic factors for phagocytes
  96. In Vitro Zinc Improvement of Granulocyte Chemotaxis and Natural Killer Cell Activity in the Elderly
  97. Modulating effects of monocytes and autologous serum on natural killer capacity in multiple myeloma patients
  98. Lipoprotein-induced inhibition of plaque-forming cell generation and natural killer cell frequency in aged donors
  99. Non-specific immunity in aging: Deficiency of monocyte and polymorphonuclear cell-mediated functions